Literature DB >> 1471320

Magnetic resonance imaging for diagnosis and follow-up of genitourinary, pelvic, and perineal rhabdomyosarcoma.

B D Fletcher1, S C Kaste.   

Abstract

Magnetic resonance (MR) imaging, ultrasound, and computed tomography (CT) were performed for diagnosis and follow-up of rhabdomyosarcoma (RMS) arising from the genitourinary tract in five children, pelvic musculature in one, and the perineum in three others. MR imaging performed at 1.0 T included the following: spin-density-, T1-, and T2-weighted images in all nine patients; gadopentatate dimeglumine (Gd-DTPA)-enhanced T1-weighted images in five; and short TI inversion recovery (STIR) images in two children. Longitudinal T1-weighted images were of additional help in localizing the primary tumor at diagnosis and detecting local spread. Residual or recurrent disease within the bladder was best detected by spin-density images. Gd-DTPA enhancement improved contrast in two studies, but paramagnetic artifacts obscured intravesical lesions in three other studies. STIR images disclosed pelvic and retroperitoneal lymphadenopathy. MR imaging is recommended as the key method of diagnosis and follow-up of pelvic RMS.

Entities:  

Mesh:

Year:  1992        PMID: 1471320     DOI: 10.1007/bf02926943

Source DB:  PubMed          Journal:  Urol Radiol        ISSN: 0171-1091


  3 in total

1.  Imaging and compartmental classification of solid pelvic tumours in children.

Authors:  C Hugosson; R Nyman; B Jacobsson; H Jorulf; P McDonald; K Sackey
Journal:  Pediatr Radiol       Date:  1996-12

Review 2.  Surgical management of gynecologic rhabdomyosarcoma.

Authors:  Matthew T Harting; Martin L Blakely; Richard J Andrassy
Journal:  Curr Treat Options Oncol       Date:  2004-04

3.  Perianal and perineal rhabdomyosarcomas: a retrospective multicenter study of 35 cases.

Authors:  Yaoyu Guo; Bang Hu; Dandan Huang; Xinhua Wang; Juan Li; Di Zhang; Xueying Li; Gong Chen; Donglin Ren
Journal:  BMC Surg       Date:  2021-01-30       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.